Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
©2023 The Authors; Published by the American Association for Cancer Research..
PURPOSE: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability.
EXPERIMENTAL DESIGN: Peptides presented on HLA-I were identified in 9 patient-derived tumor cell lines from melanoma, gynecologic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell receptors (TCR) and evaluate their therapeutic potential.
RESULTS: We found no recognition of the 507 nonC-TL tested by autologous ex vivo expanded tumor-reactive T-cell cultures while the same cultures demonstrated reactivity to mutated, cancer-germline, or melanocyte differentiation antigens. However, in vitro sensitization of donor PBL against 170 selected nonC-TL, led to the identification of TCRs specific to three nonC-TL, two of which mapped to the 5' UTR regions of HOXC13 and ZKSCAN1, and one mapping to a noncoding spliced variant of C5orf22C. T cells targeting these nonC-TL recognized cancer cell lines naturally presenting their corresponding antigens. Expression of the three immunogenic nonC-TL was shared across tumor types and barely or not detected in normal cells.
CONCLUSIONS: Our findings predict a limited contribution of nonC-TL to cancer immunosurveillance but demonstrate they may be attractive novel targets for widely applicable immunotherapies. See related commentary by Fox et al., p. 2173.
| Errataetall: |
CommentIn: Clin Cancer Res. 2023 Jun 13;29(12):2173-2175. - PMID 37040070 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 12 vom: 13. Juni, Seite 2250-2265 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lozano-Rabella, Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, Neoplasm |
|---|
| Anmerkungen: |
Date Completed 14.06.2023 Date Revised 23.01.2024 published: Print CommentIn: Clin Cancer Res. 2023 Jun 13;29(12):2173-2175. - PMID 37040070 Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-22-3298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352598123 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352598123 | ||
| 003 | DE-627 | ||
| 005 | 20240123231831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-22-3298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM352598123 | ||
| 035 | |a (NLM)36749875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lozano-Rabella, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2023 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Cancer Res. 2023 Jun 13;29(12):2173-2175. - PMID 37040070 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a PURPOSE: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability | ||
| 520 | |a EXPERIMENTAL DESIGN: Peptides presented on HLA-I were identified in 9 patient-derived tumor cell lines from melanoma, gynecologic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell receptors (TCR) and evaluate their therapeutic potential | ||
| 520 | |a RESULTS: We found no recognition of the 507 nonC-TL tested by autologous ex vivo expanded tumor-reactive T-cell cultures while the same cultures demonstrated reactivity to mutated, cancer-germline, or melanocyte differentiation antigens. However, in vitro sensitization of donor PBL against 170 selected nonC-TL, led to the identification of TCRs specific to three nonC-TL, two of which mapped to the 5' UTR regions of HOXC13 and ZKSCAN1, and one mapping to a noncoding spliced variant of C5orf22C. T cells targeting these nonC-TL recognized cancer cell lines naturally presenting their corresponding antigens. Expression of the three immunogenic nonC-TL was shared across tumor types and barely or not detected in normal cells | ||
| 520 | |a CONCLUSIONS: Our findings predict a limited contribution of nonC-TL to cancer immunosurveillance but demonstrate they may be attractive novel targets for widely applicable immunotherapies. See related commentary by Fox et al., p. 2173 | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Garcia-Garijo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Palomero, Jara |e verfasserin |4 aut | |
| 700 | 1 | |a Yuste-Estevanez, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Erhard, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Farriol-Duran, Roc |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Liberal, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ochoa-de-Olza, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Gartner, Jared J |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Canals, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, August |e verfasserin |4 aut | |
| 700 | 1 | |a Piulats, Josep Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Matías-Guiu, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Brana, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Couselo, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Garralda, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Schlosser, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Gros, Alena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 12 vom: 13. Juni, Seite 2250-2265 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:12 |g day:13 |g month:06 |g pages:2250-2265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-3298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 12 |b 13 |c 06 |h 2250-2265 | ||